NVS logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75

Analyst Consensus

Hold25 analysts
Strong Buy
0
Buy
6
Hold
17
Sell
2
Strong Sell
0
Consensus Target
$149.50
Implied Upside
-8.0%
Low Target
$136.00
High Target
$163.00

Price Target Trend

Last Month
$163.00
1 target · +0% vs price
Last Quarter
$151.67
3 targets · -7% vs price
Last Year
$146.67
6 targets · -10% vs price
All Time
$133.91
11 targets · -18% vs price

Rating Trend

Dec 25
3 buy · 7 hold · 3 sell
Jan 26
3 buy · 5 hold · 3 sell
Feb 26
3 buy · 6 hold · 4 sell
Mar 26
4 buy · 5 hold · 3 sell
Apr 26
5 buy · 5 hold · 2 sell
May 26
5 buy · 5 hold · 2 sell
Jun 26
5 buy · 5 hold · 2 sell
Jul 26
5 buy · 5 hold · 3 sell
Aug 26
5 buy · 4 hold · 3 sell
Sep 26
5 buy · 6 hold · 3 sell
Oct 26
5 buy · 6 hold · 2 sell
Nov 26
5 buy · 4 hold · 2 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 28, 2026Morgan StanleyThibault Boutherin$163.00(+4%)$156.86TheFly
Oct 6, 2026Morgan StanleyThibault Boutherin$156.00(+11%)$140.85TheFly
Sep 10, 2026HSBC$136.00(-1%)$137.48TheFly
Mar 26, 2026Morgan StanleyThibault Boutherin$170.00(+14%)$149.70TheFly
Dec 10, 2025HSBC$112.00(-15%)$131.01TheFly
Dec 3, 2025Morgan Stanley$143.00(+8%)$132.28TheFly
Oct 29, 2025CFRAWan Nurhayati$126.00(+2%)$123.33StreetInsider
Oct 30, 2024BMO CapitalEtzer Darout$120.00(+9%)$109.91StreetInsider
Sep 5, 2024Goldman SachsJames Quigley$121.00(+1%)$119.38TheFly
Jul 19, 2024BMO CapitalEtzer Darout$118.00(+11%)$106.13StreetInsider
Apr 23, 2024CFRAWan Nurhayati$108.00(+11%)$97.27StreetInsider

Recent Rating Actions

FirmActionRatingDate
Deutsche BankdowngradeHold →SellOct 30, 2026
HSBCupgradeReduce →HoldSep 10, 2026
Morgan StanleymaintainOverweightMar 26, 2026
BarclaysupgradeUnderweight →Equal WeightJan 6, 2026
JP MorganupgradeNeutral →OverweightDec 8, 2025
Goldman SachsdowngradeNeutral →SellSep 12, 2025
UBSdowngradeBuy →NeutralFeb 13, 2025
Erste GroupdowngradeBuy →HoldNov 19, 2024
BMO CapitalmaintainMarket PerformOct 30, 2024
B of A SecuritiesdowngradeBuy →NeutralSep 11, 2024
Goldman SachsdowngradeBuy →NeutralSep 5, 2024
JefferiesdowngradeBuy →HoldSep 3, 2024
JefferiesmaintainBuyJul 2, 2024
BMO CapitalmaintainMarket PerformApr 24, 2024
Morgan StanleyupgradeUnderweight →Equal WeightSep 25, 2023
Wolfe ResearchdowngradeOutperform →Peer PerformMay 9, 2022
Exane BNP ParibasdowngradeOutperform →NeutralDec 6, 2021
Bryan GarnierdowngradeBuy →NeutralDec 3, 2021
Deutsche BankdowngradeHold →SellSep 20, 2021
Argus ResearchdowngradeBuy →HoldMar 10, 2021
Cowen & Co.downgradeOutperform →Market PerformFeb 1, 2021
Morgan StanleyupgradeEqual Weight →OverweightSep 1, 2020
Guggenheim SecuritiesdowngradeBuy →NeutralFeb 25, 2020
GuggenheimdowngradeBuy →NeutralFeb 25, 2020
GuggenheimupgradeNeutral →BuyApr 25, 2019

Earnings History

Next report: Feb 3, 2027 · EPS est. $2.23
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 27, 2026$2.46$2.25$14.52B$14.53B
Jul 21, 2026$2.41$2.17$14.41B$14.07B
Apr 28, 2026$1.99$2.11$13.11B$13.44B
Feb 4, 2026$2.03$1.99$13.34B$13.70B
Oct 28, 2025$2.25$2.26$14.36B$13.64B
Jul 17, 2025$2.42$2.38$14.28B$13.94B
Apr 29, 2025$2.28$2.12$13.62B$13.90B
Jan 31, 2025$1.98$1.80$13.56B$12.84B

News

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.

Nov 3, 2026fool.com
3 Stocks to Watch Following Guidance Upgrades

The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.

Nov 2, 2026zacks.com
BioArctic collaborator Novartis terminates agreement

STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated…

Nov 2, 2026prnewswire.com
6 dividend stocks for investors who want to cut their exposure to the S&P 500

Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.

Nov 2, 2026marketwatch.com
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Nov 2, 2026reuters.com
Companies promised AI gains— here's how the payoff showed up in earnings

Companies including Santander, Novartis and Standard Chartered say artificial intelligence is beginning to contribute to revenue, costs or profitability. Santander said AI initiatives generated 194 million euros in business value in the first nine months of 2026.

Nov 1, 2026cnbc.com
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach

Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected pipeline revenue may support growth over the longer term. NVS trades at a discount to peers on forward P/E but at a premium on EV/EBITDA, producing mixed relative valuation signals.

Oct 31, 2026seekingalpha.com
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oct 30, 2026zacks.com
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Oct 30, 2026zacks.com
A pharma giant is moving past one patent cliff — but another is already looming

Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.

Oct 30, 2026cnbc.com
Novartis AG (NVS) Q3 2026 Earnings Call Transcript

Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg,…

Oct 29, 2026seekingalpha.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Oct 28, 2026zacks.com
What Novartis (NVS) Said on Its Q3 Earnings Call

Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.

Oct 27, 2026marketbeat.com
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential

LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.

Oct 27, 2026zacks.com
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.

Oct 27, 2026zacks.com
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the timeline shifting due to additional clinical work to be completed.

Oct 27, 2026benzinga.com
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oct 27, 2026zacks.com
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.

Oct 27, 2026investors.com
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.

Oct 27, 2026wsj.com
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis (NYSE: NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory filings are underway, with a U.S. submission expected by the end of the year using

Oct 25, 2026defenseworld.net